Reuters: Regulatory News: UPDATE 1-Lilly says lung cancer drug increased survival in late-stage trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Madesmith Modern handmade. New designers every week. From our sponsors

UPDATE 1-Lilly says lung cancer drug increased survival in late-stage trial Aug 13th 2013, 13:29 Tweet Share this Email Print Related Topics Stocks » Regulatory News » Markets » Healthcare » Tue Aug 13, 2013 9:29am EDT Aug 13 (Reuters) - Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014. Lilly shares were up 4 percent in premarket trading. The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone. "If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement. Earlier this year, Bristol-Myers Squibb Co. backed out of a collaboration to develop necitumumab and returned the full rights to Lilly. Necitumumab is a potential follow-up to the cancer drug Erbitux that came from Lilly's 2008 acquisition of ImClone. A separate late-stage trial of the drug was stopped in early 2011 after concerns that it was linked with blood clots. In that trial, called INSPIRE, the drug was being tested in combination with Lilly's Alimta cancer drug and the chemotherapy drug cisplatin. The company's stock closed at $54.05 on the New York Stock Exchange on Monday. Tweet this Link this Share this Digg this Email Reprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/ Comments (0) Be the first to comment on reuters.com. Add yours using the box above.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions